11 
House, NASA, Nuclear Regulatory Commission, and the Arms Control 
and Disarmament Agency. 
Issues discussed by this interagency committee, aside 
from the identification of research on rDNA molecules, have 
included: patent policies; the applicability of international 
conventions in restricting the use of rDNA techniques for the 
manufacturing of biological warfare agents; the need for special 
research facilities to conduct "high risk" and "risk assessment" 
rDNA' research ; the applicability of existing law to the 
regulation of commercial efforts to exploit the rDNA technique, 
consideration of Congressionally propos-ed legislation; and 
procedures for commercial production using rDNA techniques. 
Since 1980, no meetings have been announced, and the committee 
has no plans or projects underway to develop regulatory or 
policy initiatives or proposals affecting rDNA technology. 
Regardless of the lack of action on the part of the 
interagency committee and in addition to tort law and workers’ 
compensation, there are current federal statutes which could 
conceivably be implemented for regulating genetic technology and 
the resulting products: 
o Federal Food, Drug, and Cosmetic Act C 2 1 U.S.C. s301 et seq .) 
o Occupational Safety and Health Act C 2 9 U.S.C. S^Sl et seq .) 
o Toxic Substances Control Act (15 U.S.C. S 2 601 et seq .) 
o Marine Protection, Research, and Sanctuaries Act (53 U.S.C. 
S1401 et seq.) 
[612] 
